SEC I	Form 4
-------	--------

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

011127111							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ALAM JOHN J			2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
						VRTX]						X	0.45	(give title		er (sp	ecify	
(Last)	(F	irst)	(Middle)									_	,			,		
	RTEX PHA PORATED	RMACEUTICA	LS		3. Date o 03/17/2	of Earliest Trans 004	saction (M	onth/D	ay/Year)				50	P, Drug I	Eval. & App	r.		
130 WAVERLY STREET					4. If Ame	endment, Date o	of Original	Filed ((Month/Day	y/Yea	ar)	6. Inc	6. Individual or Joint/Group Filing (Check Applicable					
(Street)														led by One	Reporting Pe	rson		
CAMBR	IDGE M	IA	01239										-	led by Mor	e than One Re		ng	
(City)	(S	itate)	(Zip)															
		Tal	ble I - Nor	n-Deriv	ative Se	curities Ac	quired,	Disp	posed o	f, oı	r Bene	ficially	y Owned					
Da		(Month/Day/Year)		2A. Deemed Execution Date if any (Month/Day/Yea	Code (Instr. 5)			ties A I Of (I	cquired D) (Instr.	(A) or 3, 4 and	5. Amou Securitie Beneficia Owned F Reported	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	v	Amount		(A) or (D)	Price	Transact (Instr. 3	ion(s)			nsu. 4)		
Common	Stock			03/17	7/2004		Α		3,780([1]	Α	\$0.01	23	.234	D			
Common	Stock												2,	628	Ι	4	01(k)	
						urities Acq s, warrants							Owned					
							· •											
1. Title of Derivative	2. Conversion	3. Transaction	3A. Deemed Execution D		l. Transaction	5. Number of	6. Date Ex Expiration		ble and		itle and Securities		8. Price of Derivative	9. Numbe		hin	11. Nature of Indirect	

					Disposed of (D) (Instr. 3, 4 and 5)							Reported Transaction(s) (Instr. 4)		
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$9.69	03/17/2004	A		28,350		06/17/2004 ⁽²⁾	03/16/2014	Common Stock	28,350	\$0	360,995	D	

on of Responses:

1. Stock grant made under 1996 Stock and Option Plan, vesting on 3/17/2008, subject to acceleration upon achievement of certain performance-based milestones.

2. Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 03/17/04.

Remarks:

Valerie L. Andrews, Attorney-03/18/2004 In-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.